NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, Price Target & More

$158.15 -1.40 (-0.88 %)
(As of 04/23/2018 07:54 AM ET)
Previous Close$159.55
Today's Range$157.09 - $160.78
52-Week Range$113.66 - $178.25
Volume1.53 million shs
Average Volume1.73 million shs
Market Capitalization$40.31 billion
P/E Ratio200.19
Dividend YieldN/A
Beta1.49

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals logoVertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Debt-to-Equity Ratio0.01%
Current Ratio3.28%
Quick Ratio3.14%

Price-To-Earnings

Trailing P/E Ratio200.19
Forward P/E RatioN/A
P/E Growth2.14

Sales & Book Value

Annual Sales$2.49 billion
Price / Sales16.20
Cash Flow$1.0487 per share
Price / Cash150.81
Book Value$8.08 per share
Price / Book19.57

Profitability

EPS (Most Recent Fiscal Year)$0.80
Net Income$263.48 million
Net Margins10.59%
Return on Equity11.02%
Return on Assets6.28%

Miscellaneous

Employees2,300
Outstanding Shares254,880,000

How to Become a New Pot Stock Millionaire

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its board has authorized a stock repurchase plan on Thursday, February 1st 2018, which permits the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals (NASDAQ:VRTX) released its quarterly earnings results on Wednesday, January, 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.08. The pharmaceutical company earned $651.63 million during the quarter, compared to the consensus estimate of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. Vertex Pharmaceuticals's revenue was up 42.1% on a year-over-year basis. During the same period last year, the company earned $0.35 earnings per share. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Vertex Pharmaceuticals.

What price target have analysts set for VRTX?

27 analysts have issued 12-month price targets for Vertex Pharmaceuticals' stock. Their forecasts range from $98.00 to $211.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $184.3846 in the next year. View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vertex’ efforts to get its two CF drugs — Kalydeco & Orkambi — approved for additional indications are encouraging. In 2017, positive data read-outs and regulatory approvals have increased the eligible patient population for Kalydeco & Orkambi, which is driving sales growth. Vertex’s CF pipeline is also quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth, as they have the potential to treat up to 90% of CF patients. The FDA approval of the third CF medicine, Symdeko, in February was encouraging. The stock has outperformed the industry this year so far. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Estimate movement has been mixed ahead of Q1 earnings release. Vertex has a positive record of earnings surprises in the recent quarters." (4/20/2018)
  • 2. HC Wainwright analysts commented, "Halts Triple Combination Trials in France as a Protest in Pricing Negotiations What’s new? We have recently learned via a twitter comment and associated article (http://bit.ly/2Bp7vL7) that Vertex has decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis (CF) in France. During the Vertex 4Q earnings call, management identified the two second-generation correctors that would be added to the combination of tezacaftor/ivacaftor to formulate the triple combination. It appears that these trials will continue in the US and other parts of Europe but will now be excluding France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. As mentioned in the article, this is a disappointment to the French CF patients that have been consistent participants in numerous trials to date and were eagerly awaiting more rapid access to what could be the most effective modulator treatment yet for CF." (2/13/2018)
  • 3. Maxim Group analysts commented, "On January 8 at the JP Morgan Conference, Vertex reiterated 2017 Cystic Fibrosis (CF) revenue of $2.1B – $2.15B, an increase of 23% from YE-2016 and in-line with our model. As of the last update following 3Q17, Vertex guided YE-2017 Kalydeco revenue of $810M-$830M, Orkambi revenue of $1.29B- $1.32B and non-GAAP operating expenses of $1.33B-$1.36B, each in-line with our model. Street consensus estimates for 4Q17 for Kalydeco revenue is $230.6M vs. our estimate of $236.7M, Orkambi revenue of $359.9M vs. our estimate of $378.7M, non-GAAP opex of $356M vs. our estimate of $352.4M and non-GAAP EPS of $0.53 vs. our estimate of $0.63." (1/31/2018)

Who are some of Vertex Pharmaceuticals' key competitors?

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
  • Mr. Ian F. Smith, Exec. VP & COO (Age 52)
  • Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 50)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

Media stories about VRTX stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also gave news articles about the pharmaceutical company an impact score of 47.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $158.15.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $40.31 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals (VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,064 (Vote Outperform)
Underperform Votes:  593 (Vote Underperform)
Total Votes:  1,657
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
27 Wall Street analysts have issued ratings and price targets for Vertex Pharmaceuticals in the last 12 months. Their average twelve-month price target is $184.3846, suggesting that the stock has a possible upside of 16.59%. The high price target for VRTX is $211.00 and the low price target for VRTX is $98.00. There are currently 2 hold ratings and 25 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.932.932.932.85
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
25 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
25 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
25 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
23 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $184.3846$184.3846$175.68$166.4615
Price Target Upside: 16.59% upside8.42% upside5.46% upside7.36% upside

Vertex Pharmaceuticals (NASDAQ:VRTX) Consensus Price Target History

Price Target History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2018Maxim GroupBoost Price TargetBuy -> Buy$195.00 -> $200.00MediumView Rating Details
2/23/2018ArgusSet Price TargetBuy -> Buy$194.00HighView Rating Details
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform -> Outperform$200.00 -> $211.00LowView Rating Details
2/13/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$195.00 -> $196.00LowView Rating Details
2/13/2018HC WainwrightReiterated RatingHold$103.00LowView Rating Details
2/2/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$198.00 -> $200.00MediumView Rating Details
2/1/2018Bank of AmericaBoost Price TargetBuy -> Buy$180.00 -> $197.00HighView Rating Details
2/1/2018CitigroupReiterated RatingBuyHighView Rating Details
2/1/2018BMO Capital MarketsBoost Price TargetOutperform -> Buy$184.00 -> $191.00HighView Rating Details
2/1/2018Leerink SwannReiterated RatingOutperform$175.00 -> $190.00HighView Rating Details
2/1/2018Royal Bank of CanadaBoost Price TargetOutperform$200.00HighView Rating Details
2/1/2018Jefferies GroupReiterated RatingBuy$195.00HighView Rating Details
2/1/2018BarclaysBoost Price TargetOverweight -> Overweight$180.00 -> $200.00HighView Rating Details
1/9/2018JPMorgan ChaseReiterated RatingBuyLowView Rating Details
1/4/2018OppenheimerBoost Price TargetOutperform$175.00 -> $190.00LowView Rating Details
12/12/2017Deutsche BankInitiated CoverageBuy$175.00HighView Rating Details
12/11/2017CowenReiterated RatingBuy$200.00LowView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
10/26/2017Piper JaffrayReiterated RatingOverweight$205.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$200.00LowView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$200.00MediumView Rating Details
7/19/2017UBSDowngradeBuy -> Neutral$135.00 -> $174.00HighView Rating Details
7/19/2017Raymond JamesUpgradeMarket Perform -> Outperform$181.00HighView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral -> Buy$98.00HighView Rating Details
7/18/2017Stifel NicolausBoost Price TargetBuy -> Buy$130.00 -> $154.00HighView Rating Details
6/2/2017CIBCUpgradeMarket Perform -> OutperformLowView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
4/28/2016Goldman SachsDowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings History and Estimates Chart

Earnings by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings Estimates

2018 EPS Consensus Estimate: $1.69
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.30$0.34$0.32
Q2 20183$0.26$0.36$0.33
Q3 20182$0.44$0.47$0.46
Q4 20182$0.57$0.61$0.59

Vertex Pharmaceuticals (NASDAQ VRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018$0.60N/AView Earnings Details
1/31/2018Q4 2017$0.53$0.61$592.49 million$651.63 millionViewN/AView Earnings Details
10/25/2017Q3 2017$0.04$0.53$522.07 million$578.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.06$0.39$489.95 million$544.10 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
10/25/2010Q3 2010($0.91)($0.99)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.83)($0.83)ViewN/AView Earnings Details
4/21/2010Q1 2010($0.78)($0.80)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.85)($0.75)ViewN/AView Earnings Details
10/26/2009Q3 2009($0.80)($0.83)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.80)($0.92)ViewN/AView Earnings Details
4/16/2009Q1 2009($0.84)($0.97)ViewN/AView Earnings Details
2/9/2009Q4 2008($0.92)($0.95)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.91)($0.93)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.62)($0.65)ViewN/AView Earnings Details
4/21/2008Q1 2008($0.63)($0.72)ViewN/AView Earnings Details
2/11/2008Q4 2007($0.69)($0.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vertex Pharmaceuticals (NASDAQ:VRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.75%
Institutional Ownership Percentage: 94.28%
Insider Trading History for Vertex Pharmaceuticals (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Paul M SilvaSVPSell859$166.05$142,636.9516,946View SEC Filing  
4/16/2018Stuart A ArbuckleEVPSell2,125$163.01$346,396.2548,877View SEC Filing  
4/2/2018Paul M SilvaSVPSell3,438$161.21$554,239.9816,225View SEC Filing  
3/9/2018Amit SachdevEVPSell13,750$175.00$2,406,250.0060,412View SEC Filing  
3/2/2018Margaret G McglynnDirectorSell10,000$170.00$1,700,000.0016,312View SEC Filing  
2/26/2018Stuart A ArbuckleEVPSell6,459$169.00$1,091,571.0053,211View SEC Filing  
2/20/2018Paul M SilvaSVPSell3,437$158.49$544,730.1319,525View SEC Filing  
2/12/2018Jeffrey ChodakewitzCMOSell5,122$150.82$772,500.0473,485View SEC Filing  
2/12/2018Jeffrey M LeidenCEOSell23,905$150.83$3,605,591.15208,463View SEC Filing  
2/12/2018Michael PariniEVPSell12,136$153.41$1,861,783.7674,652View SEC Filing  
2/12/2018Paul M SilvaSVPSell4,213$153.41$646,316.33View SEC Filing  
2/5/2018Amit SachdevEVPSell4,520$163.01$736,805.2046,202View SEC Filing  
2/5/2018Jeffrey ChodakewitzCMOSell3,594$161.46$580,287.2456,118View SEC Filing  
2/5/2018Paul M SilvaSVPSell2,098$163.08$342,141.8417,923View SEC Filing  
2/2/2018Jeffrey ChodakewitzCMOSell3,696$166.79$616,455.8452,524View SEC Filing  
2/2/2018Paul M SilvaSVPSell9,883$173.50$1,714,700.5025,228View SEC Filing  
2/2/2018Stuart A ArbuckleEVPSell2,156$169.42$365,269.5244,108View SEC Filing  
1/29/2018Amit SachdevEVPSell15,085$170.00$2,564,450.0054,248View SEC Filing  
1/24/2018Stuart A ArbuckleEVPSell8,969$169.00$1,515,761.0046,262View SEC Filing  
1/23/2018Margaret G McglynnDirectorSell20,000$162.50$3,250,000.0016,217View SEC Filing  
1/23/2018Paul M SilvaSVPSell5,435$164.03$891,503.0519,061View SEC Filing  
1/22/2018Amit SachdevEVPSell46,172$158.65$7,325,187.8057,835View SEC Filing  
1/19/2018Amit SachdevEVPSell32,422$158.08$5,125,269.7657,835View SEC Filing  
1/16/2018Jeffrey ChodakewitzCMOSell1,719$157.28$270,364.3256,143View SEC Filing  
1/16/2018Jeffrey M LeidenCEOSell99,563$156.99$15,630,395.37176,747View SEC Filing  
1/16/2018Stuart A ArbuckleEVPSell2,125$158.28$336,345.0044,077View SEC Filing  
1/11/2018Stuart A ArbuckleEVPSell4,250$159.00$675,750.0046,202View SEC Filing  
1/5/2018Sangeeta N BhatiaDirectorSell10,753$156.00$1,677,468.0014,706View SEC Filing  
1/2/2018Jeffrey ChodakewitzCMOSell3,438$151.80$521,888.4057,862View SEC Filing  
1/2/2018Thomas GraneyCFOSell777$149.95$116,511.15View SEC Filing  
12/27/2017Paul M SilvaSVPSell1,289$152.31$196,327.5917,923View SEC Filing  
12/11/2017Jeffrey M LeidenCEOSell125,000$141.35$17,668,750.00237,407View SEC Filing  
11/15/2017Stuart A ArbuckleEVPSell221$147.29$32,551.09View SEC Filing  
11/6/2017Ian F SmithCOOSell6,405$150.00$960,750.00View SEC Filing  
11/6/2017Stuart A ArbuckleEVPSell4,250$148.17$629,722.5046,202View SEC Filing  
11/3/2017Ian F SmithCOOSell2,155$150.00$323,250.0043,043View SEC Filing  
11/3/2017Jeffrey ChodakewitzCMOSell5,390$144.71$779,986.9056,220View SEC Filing  
11/3/2017Michael PariniEVPSell2,330$149.50$348,335.0031,139View SEC Filing  
11/3/2017Sangeeta N BhatiaDirectorSell7,073$143.05$1,011,792.6511,026View SEC Filing  
10/31/2017Amit SachdevEVPSell40,000$145.05$5,802,000.0089,810View SEC Filing  
10/31/2017Ian F SmithCOOSell75,000$145.06$10,879,500.00114,188View SEC Filing  
10/31/2017Jeffrey ChodakewitzCMOSell60,000$145.05$8,703,000.00113,024View SEC Filing  
10/27/2017Stuart A ArbuckleEVPSell6,290$143.97$905,571.30116,952View SEC Filing  
10/16/2017Ian F SmithCOOSell2,125$155.61$330,671.25118,013View SEC Filing  
10/16/2017Jeffrey ChodakewitzCMOSell1,718$155.19$266,616.42116,142View SEC Filing  
10/12/2017Michael PariniEVPSell2,125$152.93$324,976.25View SEC Filing  
10/2/2017Jeffrey ChodakewitzCMOSell3,437$151.64$521,186.68View SEC Filing  
8/31/2017David AltshulerEVPSell1,796$160.00$287,360.00107,807View SEC Filing  
8/7/2017Ian F SmithCFOSell4,250$155.39$660,407.50120,138View SEC Filing  
8/7/2017Paul M SilvaSVPSell1,289$152.88$197,062.3217,923View SEC Filing  
8/3/2017Jeffrey ChodakewitzCMOSell5,390$154.17$830,976.30116,220View SEC Filing  
8/3/2017Michael PariniEVPSell2,330$155.72$362,827.6031,139View SEC Filing  
8/2/2017Ian F SmithCFOSell2,155$154.17$332,236.35118,043View SEC Filing  
8/2/2017Jeffrey ChodakewitzCMOSell1,796$154.13$276,817.48116,220View SEC Filing  
8/2/2017Paul M SilvaSVPSell1,289$151.80$195,670.2017,923View SEC Filing  
7/31/2017Jeffrey M LeidenCEOSell11,063$152.81$1,690,537.03268,455View SEC Filing  
7/31/2017Paul M SilvaSVPSell860$152.99$131,571.4017,494View SEC Filing  
7/31/2017Stuart A ArbuckleEVPSell2,125$152.99$325,103.75123,242View SEC Filing  
7/21/2017Amit SachdevEVPSell28,625$160.93$4,606,621.25119,335View SEC Filing  
7/21/2017Ian F SmithCFOSell133,750$160.98$21,531,075.00151,738View SEC Filing  
7/21/2017Jeffrey ChodakewitzCMOSell46,733$160.96$7,522,143.68128,814View SEC Filing  
7/21/2017Jeffrey M LeidenCEOSell216,624$160.96$34,867,799.04400,266View SEC Filing  
7/21/2017Paul M SilvaSVPSell43,443$161.07$6,997,364.0126,516View SEC Filing  
7/19/2017Michael PariniEVPSell10,829$161.00$1,743,469.0037,309View SEC Filing  
7/17/2017Jeffrey ChodakewitzCMOSell573$129.85$74,404.05123,084View SEC Filing  
7/3/2017Jeffrey ChodakewitzCMOSell3,438$127.80$439,376.40125,949View SEC Filing  
6/21/2017Jeffrey ChodakewitzCMOSell5,157$132.87$685,210.59127,668View SEC Filing  
6/21/2017Paul M SilvaSVPSell2,577$133.36$343,668.7222,648View SEC Filing  
6/5/2017David AltshulerEVPSell7,500$130.00$975,000.00113,511View SEC Filing  
6/2/2017Jeffrey M LeidenCEOSell147,101$129.50$19,049,579.50312,142View SEC Filing  
6/2/2017Sangeeta N BhatiaDirectorSell1,176$128.44$151,045.445,129View SEC Filing  
6/2/2017Stuart A ArbuckleEVPSell70,969$128.06$9,088,290.14145,061View SEC Filing  
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95131,490View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00395,152View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00130,532View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35124,802View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00105,054View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50136,261View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.4021,759View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00276,225View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00274,725View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00274,725View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00274,725View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00274,725View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00274,725View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00274,725View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00274,725View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.7617,125View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00274,725View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00113,358View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00274,725View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00274,725View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00274,725View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00274,725View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00274,725View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68114,566View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00274,725View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00274,725View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00274,725View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00274,725View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00274,725View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00274,725View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00268,225View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00274,725View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00268,225View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00274,725View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00274,725View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00274,725View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00274,725View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00274,725View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60273,365View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60273,355View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30273,355View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40273,355View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50273,355View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50268,225View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70270,414View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40270,414View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.3986,096View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12112,999View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00270,414View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.0015,950View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60270,414View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10270,414View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00270,414View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10270,414View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80270,414View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90270,414View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40270,414View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50270,414View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00274,425View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50274,425View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90265,284View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10265,284View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56112,999View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88261,885View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30265,284View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.8416,750View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44115,721View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50112,603View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00265,284View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00265,284View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00265,284View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00265,284View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.251,041View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00265,284View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00265,284View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00265,284View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38104,464View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00265,284View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.0075,000View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25833View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00265,284View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00345,284View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00345,284View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75625View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00345,284View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00345,284View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00345,284View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00345,284View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.005,265View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07115,098View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00416View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00345,284View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00345,284View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00345,284View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00345,284View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51127,515View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00345,284View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00208View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00345,284View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00345,284View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00143,517View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.0023,350View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00158,750View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.005,265View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.0021,210View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00158,750View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00211,481View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.0038,210View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.0010,100View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00182,925View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00141,500View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.0046,510View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00141,500View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32182,925View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.7216,624View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.8412,188View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00338,895View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00338,895View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.0054,810View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00338,895View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00338,895View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.9111,750View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00338,895View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00338,895View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00338,895View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00144,400View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00338,895View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00338,895View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.0079,710View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00338,895View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00338,895View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00144,400View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00338,895View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00338,895View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.9011,750View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vertex Pharmaceuticals (NASDAQ VRTX) News Headlines

Source:
DateHeadline
Vertex Pharmaceuticals (VRTX) Downgraded by BidaskClubVertex Pharmaceuticals (VRTX) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:24 AM
Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Zacks Investment ResearchVertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 20 at 1:18 PM
Vertex Pharmaceuticals (VRTX) SVP Paul M. Silva Sells 859 SharesVertex Pharmaceuticals (VRTX) SVP Paul M. Silva Sells 859 Shares
www.americanbankingnews.com - April 19 at 7:36 PM
Stuart A. Arbuckle Sells 2,125 Shares of Vertex Pharmaceuticals (VRTX) StockStuart A. Arbuckle Sells 2,125 Shares of Vertex Pharmaceuticals (VRTX) Stock
www.americanbankingnews.com - April 18 at 4:10 PM
Vertex Pharmaceuticals (VRTX) Receives Consensus Rating of "Buy" from AnalystsVertex Pharmaceuticals (VRTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 9:07 AM
Vertex Pharmaceuticals (VRTX) to Post Q1 2018 Earnings of $0.34 Per Share, Leerink Swann ForecastsVertex Pharmaceuticals (VRTX) to Post Q1 2018 Earnings of $0.34 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 18 at 7:40 AM
Vertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on WednesdayVertex Pharmaceuticals (VRTX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 2:46 AM
Vertex to Announce First Quarter 2018 Financial Results on April 26Vertex to Announce First Quarter 2018 Financial Results on April 26
finance.yahoo.com - April 17 at 5:39 PM
Vetr Upgrades Vertex Pharmaceuticals (VRTX) to "Strong-Buy"Vetr Upgrades Vertex Pharmaceuticals (VRTX) to "Strong-Buy"
www.americanbankingnews.com - April 17 at 4:47 PM
Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by BarclaysVertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Barclays
www.americanbankingnews.com - April 17 at 12:04 AM
Vertex Pharmaceuticals (VRTX) Upgraded to Outperform at CowenVertex Pharmaceuticals (VRTX) Upgraded to Outperform at Cowen
www.americanbankingnews.com - April 17 at 12:04 AM
Vertex Pharmaceuticals (VRTX) Given New $194.00 Price Target at Piper JaffrayVertex Pharmaceuticals (VRTX) Given New $194.00 Price Target at Piper Jaffray
www.americanbankingnews.com - April 17 at 12:04 AM
Vertex Pharmaceuticals (VRTX) Lowered to Buy at VetrVertex Pharmaceuticals (VRTX) Lowered to Buy at Vetr
www.americanbankingnews.com - April 16 at 11:29 PM
Vertex Pharmaceuticals (VRTX) Given a $195.00 Price Target by Maxim Group AnalystsVertex Pharmaceuticals (VRTX) Given a $195.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 15 at 4:33 PM
Vertex Pharmaceuticals (VRTX) Given a $184.00 Price Target at JPMorgan ChaseVertex Pharmaceuticals (VRTX) Given a $184.00 Price Target at JPMorgan Chase
www.americanbankingnews.com - April 15 at 3:59 PM
Vertex Pharmaceuticals (VRTX) Stock Rating Upgraded by VetrVertex Pharmaceuticals (VRTX) Stock Rating Upgraded by Vetr
www.americanbankingnews.com - April 15 at 9:31 AM
Vertex Pharmaceuticals (VRTX) PT Raised to $175.00Vertex Pharmaceuticals (VRTX) PT Raised to $175.00
www.americanbankingnews.com - April 14 at 3:07 PM
Vertex Pharmaceuticals (VRTX) Lifted to "Hold" at BidaskClubVertex Pharmaceuticals (VRTX) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
$608.83 Million in Sales Expected for Vertex Pharmaceuticals (VRTX) This Quarter$608.83 Million in Sales Expected for Vertex Pharmaceuticals (VRTX) This Quarter
www.americanbankingnews.com - April 13 at 4:31 AM
Vertex Pharmaceuticals (VRTX) "Buy" Rating Reiterated at Jefferies GroupVertex Pharmaceuticals' (VRTX) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 9 at 11:59 PM
Vertex Pharmaceuticals (VRTX) Lowered to "Buy" at VetrVertex Pharmaceuticals (VRTX) Lowered to "Buy" at Vetr
www.americanbankingnews.com - April 9 at 3:30 PM
Insider Selling: Vertex Pharmaceuticals (VRTX) SVP Sells 3,438 Shares of StockInsider Selling: Vertex Pharmaceuticals (VRTX) SVP Sells 3,438 Shares of Stock
www.americanbankingnews.com - April 4 at 10:56 PM
Vertex Pharmaceuticals (VRTX) Stock Rating Reaffirmed by Piper JaffrayVertex Pharmaceuticals (VRTX) Stock Rating Reaffirmed by Piper Jaffray
www.americanbankingnews.com - April 4 at 8:34 PM
Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery CollaborationQ-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration
www.businesswire.com - April 4 at 8:42 AM
Concert Therapeutics Will See A Second Wind In Coming MonthsConcert Therapeutics Will See A Second Wind In Coming Months
seekingalpha.com - April 3 at 5:15 PM
Zacks Investment Research Upgrades Vertex Pharmaceuticals (VRTX) to Strong-BuyZacks Investment Research Upgrades Vertex Pharmaceuticals (VRTX) to Strong-Buy
www.americanbankingnews.com - March 30 at 12:48 PM
Vertex Pharmaceuticals (VRTX) Rating Lowered to Sell at BidaskClubVertex Pharmaceuticals (VRTX) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM
Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications OfficerVertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer
finance.yahoo.com - March 29 at 5:12 PM
Why Regeneron Pharmaceuticals’ Stock Price FellWhy Regeneron Pharmaceuticals’ Stock Price Fell
finance.yahoo.com - March 29 at 5:12 PM
Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors?Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors?
finance.yahoo.com - March 28 at 8:50 AM
$608.99 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter$608.99 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - March 27 at 7:08 AM
Vertex Pharmaceuticals (VRTX) Given New $200.00 Price Target at BarclaysVertex Pharmaceuticals (VRTX) Given New $200.00 Price Target at Barclays
www.americanbankingnews.com - March 25 at 10:57 PM
Vertex Pharmaceuticals (VRTX) Receives Buy Rating from Jefferies GroupVertex Pharmaceuticals (VRTX) Receives Buy Rating from Jefferies Group
www.americanbankingnews.com - March 25 at 10:22 PM
Vertex Pharmaceuticals (VRTX) PT Raised to $200.00Vertex Pharmaceuticals (VRTX) PT Raised to $200.00
www.americanbankingnews.com - March 25 at 10:22 PM
Vertex Pharmaceuticals (VRTX) Raised to "B-" at TheStreetVertex Pharmaceuticals (VRTX) Raised to "B-" at TheStreet
www.americanbankingnews.com - March 24 at 11:25 AM
Vertex Pharmaceuticals Incorporated (VRTX) Receives Average Rating of "Buy" from AnalystsVertex Pharmaceuticals Incorporated (VRTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 8:28 AM
Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate A Dud - BenzingaProteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud' - Benzinga
www.benzinga.com - March 21 at 9:24 AM
Vertex Pharmaceuticals (VRTX) Raised to Hold at BidaskClubVertex Pharmaceuticals (VRTX) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 18 at 4:24 PM
NYSE trader: Out of control deficit spending will come to bite us somedayNYSE trader: Out of control deficit spending will come to bite us someday
finance.yahoo.com - March 16 at 6:10 PM
Trying the Long Side of Vertexs Stock AgainTrying the Long Side of Vertex's Stock Again
finance.yahoo.com - March 16 at 6:10 PM
7 Things Vertex Pharmaceuticals CEO Just Said That Will Probably Make You Want to Buy the Stock7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock
www.msn.com - March 15 at 5:47 PM
No. 1-Ranked Drug-Trial Stock And IBD 50 Member Examines Buy ZoneNo. 1-Ranked Drug-Trial Stock And IBD 50 Member Examines Buy Zone
finance.yahoo.com - March 15 at 8:36 AM
Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in StockVertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in Stock
www.americanbankingnews.com - March 12 at 7:21 PM
Vertex to Present at the Cowen Healthcare Conference on March 13Vertex to Present at the Cowen Healthcare Conference on March 13
finance.yahoo.com - March 12 at 6:18 PM
 Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million
www.americanbankingnews.com - March 10 at 10:22 AM
 Analysts Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.52 Per Share Analysts Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.52 Per Share
www.americanbankingnews.com - March 8 at 1:08 AM
Renaissance Technologies LLC Has $426.79 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)Renaissance Technologies LLC Has $426.79 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - March 6 at 2:52 PM
MYDA Advisors LLC Buys New Stake in Vertex Pharmaceuticals Incorporated (VRTX)MYDA Advisors LLC Buys New Stake in Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - March 6 at 2:46 PM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) Director Sells 10,000 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 5 at 9:11 PM
Green Valley Investors LLC Trims Holdings in Vertex Pharmaceuticals Incorporated (VRTX)Green Valley Investors LLC Trims Holdings in Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - March 5 at 4:07 PM

SEC Filings

Vertex Pharmaceuticals (NASDAQ:VRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vertex Pharmaceuticals (NASDAQ:VRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vertex Pharmaceuticals (NASDAQ VRTX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.